Fig. 4: The a09b08 ImmTAV molecule elicits T cell responses against cells displaying HBV Env371-379 pHLA-E complexes.
From: Viral sequence determines HLA-E-restricted T cell recognition of hepatitis B surface antigen
a ELISPOT assay measuring dose-dependent IFN-γ release induced by a09b08 ImmTAV in co-cultures of PBMC from 3 HBV-naïve donors and THP-1-E*01:03 cells pulsed with Env371-379 (purple line), Env371-379 (S3N) (red line) and Env371-379 (L6I) (blue line) peptides (10 μg/mL). b IFN-γ ELISPOT assays showing titratable activation of PBMC from 3 HBV-naïve donors by a09b08 ImmTAV (1 nM) in the presence of THP-1-E*01:03 cells pulsed with the indicated amounts of peptide. Controls (a, b clear symbols) include PBMC + target cells (no ImmTAV; unpulsed or pulsed with 10 μg/mL peptide), and PBMC + ImmTAV + target cells (unpulsed). c ELISPOT assay measuring dose-dependent IFN-γ release from HBV-naïve donor PBMC in the presence of HepG2 targets stably transfected with minigenes encoding the indicated peptides Env371-379, Env371-379 (S3N), and Env371-379 (L6I). Untransfected HepG2 (no minigene) and PBMC + minigene target cells (no ImmTAV) were included as controls (clear symbols). d Cumulative IFN-γ responses induced by a09b08 ImmTAV in PBMC cocultured with HepG2 Env371-379 (L6I) (blue) or Env371-379 (S3N) (red) minigene targets in the presence or absence of blocking mAbs against HLA-E or HLA-A*02:01 (10 µg/mL); ****p = <0.0001, two-way ANOVA. Results (a–d) are representative of one of three PBMC donors tested in triplicate. Data were presented as mean values ± SD. Average EC50 are indicated in the inset at the top left corner of the figures (a–c). All donor EC50 values and averages are displayed in Supplementary Table 5. Source data are provided as a Source Data file.
